Use P27KIP1 Degradation for Breast Cancer Diagnosis and Therapy
Abstract
P27 IS A CDK inhibitor that controls the Gl/S transition. Low or absent expression of p27 has been observed in many malignant tumors including breast cancer. SCF(SKP2) is a ubiquitin E3 ligase that interacts and targets p27 for ubiquitin-dependent proteolysis. One aim of the proposal is to determine whether there is an inverse relationship between SCF(SKP2) and p27 in breast cancer and the experiments are in progress. Another aim is to determine the domain on SKP2 that binds to p27. We have determined the carboxy-terminal region of SKP2 is required for binds to phosphorylated p27. The critical aim is to determine whether inhibition of SCF(SKP2) in breast cancer cells causes cell cycle arrest. Our studies suggest that inhibition of SCF(SKP2) in breast cancer and other cancer cells causes accumulation of p27 and Gi cell cycle block. Thus SCF(SKP2) may be used as a target for breast cancer therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2002
- Accession Number
- ADA412764
Entities
People
- Hui Zhang
Organizations
- Yale University